The Role of Pulmonary Rehabilitation and Airways Clearance Techniques in the Multidisciplinary Management of Non CF Bronchiectasis

November 23, 2015 updated by: Eva Polverino, Hospital Clinic of Barcelona
Pulmonary rehabilitation programs are part of the multidisciplinary treatment of some chronic respiratory diseases such as COPD (chronic obstructive pulmonary disease). Although clinical guidelines of other diseases such as non-cystic fibrosis bronchiectasis (nCFBE) discuss the benefits of these programs in quality of life and exercise tolerance, evidence of such intervention in nCFBE patients is insufficient. Longer studies are needed with larger sample sizes and optimized to maximize the response and maintain long-term benefits. The present study aims to examine the effects in exercise tolerance of a pulmonary rehabilitation program combined with respiratory physiotherapy in patients with nCFBE. It is a randomized controlled clinical trial with a total duration of 24 months. The intervention will be performed during 12 weeks and then will be a period of 12 months of maintenance. This is a multicenter study involving the following Hospitals: Hospital Clinic, Hospital la Plató and Hospital del Mar of Barcelona, Hospital Josep Trueta of Girona, Royal Infirmary of Edinburgh and Fondazione Maugeri di Lumezzane of Italy. Subjects will be randomized into three groups in a ratio (1: 1: 1) (1) Pulmonary Rehabilitation (2) Chest Physiotherapy and (3) Pulmonary Rehabilitation + Chest Physiotherapy. Hospital la Plató from Barcelona will be responsible for carrying out the Control Group. The primary endpoint will be the test of "endurance shuttle walk test".

Study Overview

Study Type

Interventional

Enrollment (Anticipated)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Aged between 50-80 years;
  • No performing regular physiotherapy treatment or physical training (≤ 1 time/week);
  • Stable disease [no changes in the chronic therapy (both inhaled and systematic) in the usual respiratory symptoms (according to the medical evaluation) and spirometry in the last 4 weeks prior to study recruitment];
  • Regular cough and expectoration;
  • Ability to follow the exercise program;
  • Ability to perform all clinical tests, to understand the process and the purposes of the study;
  • A history of at least 2 exacerbations during the previous year requiring antibiotic treatment and;
  • Signed informed consent.

Exclusion Criteria:

  • Active smokers, ex-smokers of less than 1 year prior to recruitment and/or a history of >20 smoking packs/year;
  • FEV1 <30% or/and TLC<40% ;
  • Diagnosis of cystic fibrosis, sarcoidosis, pulmonary fibrosis, active tuberculosis or non tuberculosis mycobacterial infection,
  • Diagnosis of asthma or COPD as a primary respiratory disease and associated secondary bronchiectasis,
  • Patients with unstable cardiac disease or locomotor difficulties that preclude exercise (eg, severe arthritis or severe peripheral vascular disease);
  • Chronic respiratory failure and/or oxygen therapy;
  • Frequent haemoptysis (≥ 2 times/month);
  • Participation in a PR program during the year prior to inclusion or during the study protocol;
  • Participation in a CP program during 1 month prior to inclusion;
  • Any physical and psychological disorder that interferes with protocol compliance;
  • Participation in a clinical trial implying any change in usual pharmacological treatment in the last 6 months before recruitment;
  • Being on the waiting list for lung transplantation or have been transplanted.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Pulmonary Rehabilitation
These sessions will be individually designed and they will be a combination of global aerobic interval training using a cycloergometer. The aim is to achieve a training intensity of 80% HR or greater of the obtained during the ISWT. This intensity will be progressively increased during the firsts four weeks until achieving the target. The duration will be of about 45 minutes per session. Oxygen Saturation, HR and Borg scale for dyspnoea and fatigue will be measured before, during and at the end of the session in order to monitories the effort.
The patient will come 3 times per week during 12 weeks Each session 45min
Active Comparator: Chest Physiotherapy
The ELTGOL technique ("total slow expiration with glottis open in lateral decubitus") for airways clearance will be used in order to move respiratory secretions from the distal bronchial tree. It will be applied during 15 minutes each side (right and left lungs) assuming an approximate session length of 30 minutes. The patient could perform the cough technique when it's necessary.
The patient will come 3 times per week during 12 weeks Each session 30min
Active Comparator: Pulmonary Rehabilitation and Chest Physiotherapy

This group will perform a combination of the two programs in the same session with a total duration of 1h and 15 minutes. The session will be divided in different parts: First, we will execute 15min of chest physiotherapy (7.5min for each side); second, the pulmonary rehabilitation session (45min) and finally, another 15min of chest physiotherapy (7.5min for each side). The patient will have a rest when it's necessary and we will continue with the session when there is a decrease of 2 points in the Borg scale.

Intensity of physiotherapy exercises and drainage techniques will be maintained similar to the PR and CP programs.

The patient will come 3 times per week during 12 weeks Each session 1h15min
No Intervention: Control Group

For the control group, participants will attend educational sessions to improve patients' understanding and awareness of the respiratory diseases. These sessions will be performed at beginning and at 12 weeks by the physiotherapist and the pulmonologist.

The physiotherapist will also do monthly telephone calls for patient's monitoring.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change from Baseline Exercise tolerance capacity measured as the distance walked in meters during the shuttle test at constant speed (ESWT) at 12 weeks.
Time Frame: At Screening and 12 weeks of intervention
At Screening and 12 weeks of intervention

Secondary Outcome Measures

Outcome Measure
Time Frame
Exacerbations incidence and symptoms
Time Frame: During all study (12 weeks of intervention)
During all study (12 weeks of intervention)
Change from Baseline Health related quality of life at 12 weeks.
Time Frame: At Screening and 12 weeks of intervention with Quality of Life Questionnaire (QoL-B)
At Screening and 12 weeks of intervention with Quality of Life Questionnaire (QoL-B)
Change from Baseline Impact of expectoration on the quality of life at 12 weeks.
Time Frame: At Screening and 12 weeks of intervention with Leicester Cough Questionnaire (LCQ)
At Screening and 12 weeks of intervention with Leicester Cough Questionnaire (LCQ)
Sputum colour
Time Frame: During all study (12 weeks of intervention) with Murray's colour scale
During all study (12 weeks of intervention) with Murray's colour scale
Change from Baseline FEV1, FVC and FEV1/FVC at 12 weeks.
Time Frame: At Screening and 12 weeks of intervention with Pulmonary Function Tests
At Screening and 12 weeks of intervention with Pulmonary Function Tests
Change from Baseline Physical activity level measured by accelerometry at 12 weeks.
Time Frame: At Screening and 12 weeks of intervention with accelerometry
At Screening and 12 weeks of intervention with accelerometry
Sputum quantity
Time Frame: During all study (12 weeks of intervention) with weight of sputum containers in grams
During all study (12 weeks of intervention) with weight of sputum containers in grams

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2015

Primary Completion (Anticipated)

December 1, 2017

Study Registration Dates

First Submitted

November 18, 2015

First Submitted That Met QC Criteria

November 23, 2015

First Posted (Estimate)

November 25, 2015

Study Record Updates

Last Update Posted (Estimate)

November 25, 2015

Last Update Submitted That Met QC Criteria

November 23, 2015

Last Verified

November 1, 2015

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Non-cystic Fibrosis Bronchiectasis

Clinical Trials on Pulmonary Rehabilitation

3
Subscribe